Literature DB >> 856088

Vigorous medical management of acute fulminant hepatitis.

M O Auslander, G L Gitnick.   

Abstract

Twenty patients with acute fulminant hepatic failure and stage II, III, or IV hepatic encephalopathy attributable to viral hepatitis were studied to assess the risk factors, as well as the affects of vigorous medical management. These patients were treated according to a protocol that directed aggressive medical management of fluid balance with electrolyte solutions, plasma, and blood; acid-base balance; coagulation defects with fresh frozen plasma; blood replacement as needed; dietary protein elimination; and orally administered neomycin sulfate. Among the 20 patients there were eight survivors (40%). Seven of the 13 patients who were positive for the hepatitis B surface antigen (HB-Ag) survived (54%), while one of the seven patients whoe were negative for HB-Ag survived (14%). The stage of encephalopathy on admission did not correlate with survival. Patients under the age of 40 years had a 43% survival rate, while those over 40 years had a 33% survival rate. Conservative but vigorous medical management may improve survival in fulminant hepatic failure.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 856088

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  6 in total

1.  Fulminant hepatitis--is the survival improving?

Authors:  Y Muto
Journal:  Gastroenterol Jpn       Date:  1992-02

2.  Orthotopic liver transplantation for acute and subacute hepatic failure in adults.

Authors:  R R Peleman; J S Gavaler; D H Van Thiel; C Esquivel; R Gordon; S Iwatsuki; T E Starzl
Journal:  Hepatology       Date:  1987 May-Jun       Impact factor: 17.425

Review 3.  Fulminant hepatitis.

Authors:  S Sinclair; A Wakefield; G Levy
Journal:  Springer Semin Immunopathol       Date:  1990

4.  Attempted treatment of fulminant viral hepatitis with human fibroblast interferon.

Authors:  F Milazzo; M Galli; P G Fassio; A Cargnel; A Pugliese; P A Tovo; G M Vigevani; R Esposito; A Lazzarin; F Caredda
Journal:  Infection       Date:  1985 May-Jun       Impact factor: 3.553

5.  Treatment of fulminant viral hepatic failure with prostaglandin E. A preliminary report.

Authors:  S B Sinclair; G A Levy
Journal:  Dig Dis Sci       Date:  1991-06       Impact factor: 3.199

6.  Biochemical and clinical response of fulminant viral hepatitis to administration of prostaglandin E. A preliminary report.

Authors:  S B Sinclair; P D Greig; L M Blendis; M Abecassis; E A Roberts; M J Phillips; R Cameron; G A Levy
Journal:  J Clin Invest       Date:  1989-10       Impact factor: 14.808

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.